血小板活化因子受体研究进展

血汴板活化因子是通过靶细胞膜上的受体而发挥其作用的,该受体属Ｇ联的受体家族,含３４２个氨基酸,有７个疏水的跨膜片段。其作用机制是通过激活磷酯酰肌醇、钙信使系统及相关蛋白激酶,使某些蛋白质发生磷酸化并产生相应的生物学效应。     

血小板活化因子受体研究进展

血小板活化因子（ＰＡＦ）是一种磷脂细胞因子,具有广泛的生物活性,其生物效应是通过ＰＡＦ受体产生。本概述了ＰＡＦ受体的组织细胞分布、亚型、分子结构、表达调控及细胞内信息转导等。     

血小板活化因子的代谢途径和生物学作用的研究进展

血小板活化因子（ＰＡＦ）是一种内源性磷脂介质,具有广泛的生物学作用,除活化血小板以外,还可活化多形核白细胞、单核细胞和巨噬细胞,并可参与细胞内信息传递、增加血管渗透性、降低血压。在免疫病理过程、支气管收缩过程、抗高血压活性和水肿原效应等方面皆起重要作用。     

血小板活化因子对大鼠肺动脉压及心输出量的影响

本实验用不同剂量的血小板活化因子(PAF)、环氧合酶抑制剂消炎痛及环磷酸鸟苷(cGMP)抑制剂亚甲蓝研究PAF对大鼠肺动脉压及心输出量的影响。     

清醒羊低氧性肺动脉高压及逆转中肺血管对外源性血小板活化因子的反应

本实验复制了清醒羊低氧性肺动脉高压（ＨＰＨ）及其逆转模型,动态观察了在ＨＰＨ发生、发展及逆转中肺、体循环对外源性血小板活化因子（ＰＡＦ）的反应。结果表明：（１）ＰＡＦ对清醒羊常氧期、ＨＰＨ及ＨＰＨ逆转期均为一强效应肺血管收缩剂,且呈剂量依赖性;（２）ＨＰＨ期：ＰＡＦ对肺血管加压反应增值百分离较常氧期及ＨＰＨ逆转期低;（３）ＰＡＦ对三期体动脉压、心率无明显影响,却能降低各期心输出量。     

血小板活化因子对豚鼠心室肌细胞动作电位和钾通道的影响

应用全细胞膜片钳技术研究了血小板活化因子(platelet activatingfactor,PAF)对豚鼠心室肌细胞动作电位和钾电流的影响.结果发现,当电极内液ATP浓度为5 mmol/L(模拟正常条件)时,1 μmol/L PAF使APD90由对照的225.8±23.3 ms延长至352.8±29.8ms(n=5,P＜0.05);使IK尾电流在指令电压 30 mV由对照的173.5±16.7 pA降至152.1±11.5 pA(P＜0.05,n=4);使Ikl在指令电压为-120 mV时由对照组的-6.1±1.3 nA降至-5.6±1.1 nA(P＜0.05,n=5);但PAF在生理膜电位范围(-90mV～ 20mV)对IK1没有影响.当电极内液ATP浓度为0mmol/L时,IK·ATP开放(模拟缺血条件),1 μmol/LPAF却显著缩短APD90,由对照的153±24.6 ms缩短至88.2±19.4 ms(n=5,P＜0.01).而用1 μmol/L格列本脲(IK·ATP的特异阻断剂)预处理后,恢复了PAF可显著延长动作电位时程的作用.结果提示,PAF可能扩大缺血心肌和正常心肌细胞动作电位时程的不均一性,是缺血/再灌注性心律失常发生的重要原因.     

急性毛细支气管炎并心衰患儿血小板活化因子,血小板源生长因子的表达及临床意义

目的:探讨血小板活化因子(PAF)、肿瘤坏死因子-α(TNF-α)及血小板源生长因子(PDGF)水平变化在毛细支气管炎并急性心衰的变化,探讨它们在该病的发病中的作用方法:58例心衰组患儿分别于治疗前和临床症状消失后采用双抗体夹心ABC-ELISA法检测PAF、TNF-α及PDGF血清含量,设正常对照组40例比较。结果:心衰组PAF治疗前为370.57±23.6ng/L,明显高于对照组的56.78±19.6ng/L,组间比较差异具有非常显著性意义(t=15.95,P<0.001);治疗后恢复至49.63±14.5 ng/L,与正常对照差异不明显;治疗前后比较,差异具有非常显著性意义(t=3.70,P<0.001)TNF-α治疗前为457.4±40.5 ng/L,明显高于对照组的148.8±21.6ng/L,组间比较差异具有显著性意义(t=2.135,P<0.05);治疗后恢复至162.6±37.61ng/L,与正常对照差异不明显;治疗前后比较,差异具有非常显著性意义(t=7.25,P<0.01)。PDGF治疗前为596.23±199.43)ng/L,较对照组259.76±69.58ng/L增高,组间比较,差异具有非常显著性意义(t=25.52,P<0.01);治疗后降为272.83±116.96ng/L,较治疗前明显恢复,组间比较差异均具有显著性意义(t=7.66,P<0.01)结论:结果表明,PAF、TNF-α、PDGF作为炎症介质不仅参与心衰的发病过程,还提示细胞外基质的异常在心衰发病学中的重要地位     

Synthesis of phosphono analogs of a phospholipid platelet activating factor]

Structural analogues of phospholipidic platelet activating factor, (2-acetoxy-3-octadecyloxy)propyl-1-phosphonocholine and (2-methoxy-3-octadecyloxy)propyl-1-phosphonocholine, were synthesized. High efficiency of the polymer-bound dibenzo-18-crown-6-ether as the O-alkylation catalyst was demonstrated. Reaction of allyl-octadecyl ether with methanol and iodine in the presence of zinc oxide was shown to give a mixture of 1-iodo-2-methoxy- and 1-methoxy-2-iodoprop-3-yl ethers of octadecanol in the 3:1 ratio.     

Cardiodepressive effect of platelet activating factor

The cardiodepressive effect of PAF has been studied on the electrical and mechanical activities of isolated auricles of guinea pig. Intracellular resting potential, action potential (AP) and isometric contractions elicited by electrical stimulation (0.5 Hz) were measured. PAF (10(-7) M) induced negative inotropic effect, which reached its peak after 5 min with 23.5 +/- 6.6% in respect to prechallenge values (n = 8). After 20 min negative inotropic effect relaxed to 39.6 +/- 8.8%. 1 min after the beginning of washing in Tyrode solution, positive inotropic effect of PAF was evident, that reached its peak (217 +/- 49.5%) after 2 min, decayed after 5-10 min to normal values. PAF did not modify the resting membrane potential, produced a decrease in the amplitude and Vmax of the upstroke AP, shortened the AP duration. Ca-AP and contractions, elicited in partially depolarized myocardium were decreased by PAF (10(-7) M). PAF-produce the change of the AP and the negative effect on auricle contractile force was inhibited in muscles pretreated with 3mM 4 aminopyridine. Histamine (10(-4) M) was also capable of neutralizing the depressant effect of PAF. The obtained results suggested that PAF effects on the membrane of cardiac cells could be related to a change in Ca and K conductance.     

The effect of platelet activating factor on ovulation.

The mechanism of ovulation has been compared to an inflammatory reaction. Platelet activating factor (PAF) is an important mediator of inflammation as it may induce the production of prostaglandins and lysosomal enzyme. We evaluated the potential role of PAF in PMSG-HCG induced ovulation using CV3988, a specific PAF receptor antagonist in a superovulated ICR mice (9-12 weeks old). CV3988 blocked the ovulation in a dose dependent manner, and the significant reduced ovulatory efficiency was observed at more than 500 micrograms dose (p less than 0.001). The ovulatory efficiency reduced by CV3988 was reversed by PAF in a dose dependent manner. In vitro fertilization (IVF) rate of follicular oocytes with treatment of CV3988 was not different from that of ovulated ova without treatment. These results suggest that PAF may be involved in the ovulation process but the presence of PAF may not be essential for the fertilization of the ova as IVF.     

Synthesis of a fluorescently-labeled platelet activating factor

The synthesis of fluorescently labelled PAF-acether, 1-alkyl-2-acetyl-sn-glycero-3-phospho-[N-(9-anthrylmethyl)-N, N-dimethylethanolamine] with the label in the choline moiety is described, plasmalogen lysophosphatidylcholine of bovine heart being used as starting material.     

Binding of platelet activating factor to albumin

Binding of platelet activating factor (1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine) to albumin is an important facet of the biological activity of this phospholipid. Measurement of that binding has been hampered by the physical nature of the lipid, which made estimation of the free and bound concentrations difficult. With the use of ultracentrifugation to generate an albumin gradient and to produce a region free of protein, the successful measurement of free PAF and PAF bound to albumin was accomplished. This study has demonstrated that PAF binds to albumin at four binding sites and that the average equilibrium dissociation constant for this binding is 1.10(-7) M. Consideration of these data has led to the hypothesis that the receptor active form of PAF is the albumin-PAF complex, rather than free PAF.